Interleukin-6
Alternative Names: BCDF; Interferon-beta-2; interferon-β - 2; rhIL-6; β - 2 IFLatest Information Update: 24 Oct 2021
At a glance
- Originator Cangene Corporation
- Class Antineoplastics; Interleukins
- Mechanism of Action Interleukin stimulants; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bacterial infections; Chemotherapy-induced damage; Thrombocytopenia
Most Recent Events
- 07 Oct 2002 Discontinued - Phase-I for Chemotherapy induced damage in France and Switzerland (SC)
- 07 Oct 2002 Discontinued - Phase-I for Thrombocytopenia (Chemotherapy-induced) in France and Switzerland (SC)
- 07 Oct 2002 Discontinued - Preclinical for Bacterial infections in Italy (unspecified route)